Astorg to Acquire Solabia, a Leading Biotech Ingredient Solutions Provider

Founded in 1972, Solabia specializes in natural active ingredients for the cosmetics, nutraceutical, pharmaceutical, as well as food and clinical testing industries. Leveraging advanced biotechnology capabilities - including fermentation, enzymatic synthesis, plant extraction, and green chemistry - Solabia develops high-performance ingredients that support precise formulation needs and enable differentiated product outcomes for its customers.

The Company holds leading positions across its market segments, driven by technological differentiation. Solabia’s active ingredients play a critical role in its customer formulations and end-products quality, contributing to high customer retention and long-term supplier integration. Solabia is positioned in dynamic and resilient end-markets and benefits from the continued penetration of natural ingredients in substitution to synthetic compounds.

Headquartered in Paris, Solabia operates 11 manufacturing sites and 8 R&D labs worldwide and employs over 900 staff. It is one of the few independent natural active ingredients platforms at scale combining deep technological expertise with strong global distribution capabilities.

Building on Solabia’s strong track record, marked by double-digit growth in the past five years, Astorg, TA and Solabia’s management team will focus on further accelerating international expansion – particularly in the US and Asia – and advancing the Company’s innovation roadmap, while continuing to benefit from strong market tailwinds.

Jean-Baptiste Dellon, President & Chief Executive Officer, Solabia, said:

“We are excited to welcome Astorg as a strategic partner and to continue our successful collaboration with TA. Astorg brings a unique combination of deep sector expertise, a strong track record of value creation, and an entrepreneurial mindset that aligns closely with Solabia’s values and ambitions. Their support will be instrumental as we accelerate innovation, expand our global footprint, and continue delivering high-performance, science-based solutions to our customers around the world.”

Nicolas Marien, Partner, Astorg and Paul Arhanchiague, Managing Director, Astorg added:

“With its unique position in a structurally growing market - driven by rising global demand for natural active ingredient solutions - deep biotech expertise, and a strong track record of sustained growth, Solabia exemplifies the type of international B2B leader that Astorg is proud to support. We look forward to partnering with Jean-Baptiste and the Solabia team to build upon this solid foundation and drive the next phase of growth through a targeted value creation plan.”

Patrick Sader, Managing Director, TA, and Jérémy Dréan, Director, TA, said:

“Since our initial investment in 2018, it has been a privilege to support Solabia’s transformation into a leading vertically integrated natural and biotech life sciences and health platform. Under the leadership of Jean- Baptiste Dellon and his team, Solabia has scaled, achieving strong organic and external growth. We remain confident in the company’s strategic vision and long-term growth potential, and are thrilled to be part of its continued journey alongside Astorg.”

The transaction was made via Astorg VIII and represents the funds’ ninth investment to date.

The transaction is subject to customary regulatory approvals and is expected to close in the coming months. Financial terms were not disclosed.

Astorg was advised by Evercore and Wil Partners (Financial advisors), and Weil Gotshal & Manges (Legal advisor). Solabia management was advised by Sycomore (Financial advisor) and Jeausserand-Audouard (Legal & Tax advisors). TA was advised by BofA Securities (Financial advisor) and Latham & Watkins (Legal advisor).

*ENDS*